Author

Álvaro Lorente‐Macías

Cancer Research UKORCID 0000-0001-9510-714XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Asier Unciti‐BrocetaiD· 2 shared Diego A. OyarzúniD· 1 shared Erika Lace· 1 shared Fraser Nunn· 1 shared John C. DawsoniD· 1 shared Muhammad FurqaniD· 1 shared Neil O. CarragheriD· 1 shared Rachel L. TothiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Asier Unciti‐BrocetaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyDigital DiscoveryPeer-reviewedJan 1, 2026

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models

Vanessa Smer-Barreto, Richard J. R. Elliott, John C. Dawson…·Neil O. Carragher

This study identifies three compounds targeting glioblastoma stem cells using machine learning and high-throughput screening of patient-derived models.

4 citationstop 2%

humanproteomics

𝕏 PostBluesky

NeurosciencebioRxivPreprintJul 1, 2025

The c-Src inhibitor eCF506 diminishes opioid tolerance creating bias against β-arrestin2 recruitment

Samuel Singleton, Fraser Nunn, Erika Lace…·Tim G. Hales

The paper tests eCF506, a c-Src inhibitor, showing it reduces opioid tolerance by decreasing β-arrestin2 recruitment without affecting cAMP inhibition.

DOI 10.1101/2025.07.01.662507

mouseexperimental assay

𝕏 PostBluesky